
Smart Brain-Zapping Implants Could Revolutionize Parkinson's Treatment
Deep-brain stimulation involves inserting thin wires through two small holes in the skull into a region of the brain associated with movement. The hope is that by delivering electrical pulses to the region, the implant can normalize aberrant brain activity and reduce symptoms. Since the devices were first approved almost three decades ago, some 200,000 people have had them fitted to help calm the tremors and rigidity caused by Parkinson's disease. But about 40,000 of those who received devices made after 2020 got them with a special feature that has largely not yet been turned on. The devices can read brain waves and then adapt and tailor the rhythm of their output, in much the same way as a pacemaker monitors and corrects the heart's electrical rhythms, says Helen Bronte-Stewart, a neurologist at Stanford University in California.
Bronte-Stewart received approval to start a clinical trial of this new technology, known as adaptive deep-brain stimulation (aDBS), the same week that Krehbiel was preparing for surgery. He recalls the phone call in which she asked him if he wanted to be her first participant: 'I said, 'Boy, do I!''
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
Five years on, the results of this 68-person trial, called ADAPT-PD, are under review for publication. Although the exact details are still under wraps, they were convincing enough to earn approval for the technology earlier this year from both US and European regulators.
The results of this study could be a boon for the estimated one million people in the United States and 1.2 million people in Europe who now live with Parkinson's disease — and for Medtronic, the health-care technology company based in Minneapolis, Minnesota, that manufactures the implants. The seeming success also clears a path for other companies around the world that are racing for approval on advanced devices, says Martijn Beudel, a neurologist at Amsterdam University Medical Center who worked on the trial.
The approaching wave of therapies promises to level up DBS for Parkinson's and other motor conditions. The technology might even help to treat neurological disorders such as Tourette's syndrome and psychiatric conditions, including obsessive–compulsive disorder (OCD) and depression. Several clinicians suggest that the new technology could have even more profound health implications — that is, if funding for US brain-implant research isn't cut.
Deep trade-offs
Since DBS was first approved in Europe and the United States in the late-1990s, the vast majority of devices have been given to people with Parkinson's disease. Parkinson's is a progressive disorder, typified by the death of neurons that produce the neurotransmitter dopamine, which is key to controlling movements.
Existing drugs that aim to increase dopamine levels can only manage the symptoms. They can't match the constant dopamine production of a healthy brain. 'No matter how clever we are with it, we have never been able to exactly mimic the way the brain supplies it,' says Bronte-Stewart. This means that symptoms vary throughout the day — from the unwanted involuntary movements induced by the morning flood of dopamine-mimicking drugs to increased rigidity later in the day as the drugs wear off. The medication also comes with other side effects that vary from person to person. For Krehbiel, it was nausea so severe he had to lie down multiple times a day.
When these become overwhelming, a neurologist might recommend DBS. Implants typically dispense pulses of electrical energy deep into the brain 24 hours a day to regulate aberrant brain signals associated with uncontrollable body movements. Before this year, this always-on approach was the only commercially available form of the therapy.
But continuous DBS can sometimes amplify the drugs' effects — or generate new symptoms. Some of these are harmless: one man with OCD developed a passion for the music of Johnny Cash when his stimulator was turned on, but was uninterested in the artist when it was off. Other symptoms are cause for more concern, including sudden-onset gambling disorders and other temporary changes in impulse control. More frequently, the addition of stimulation can induce speech impairments, such as slurring, raise the risk of falling and cause some involuntary movements.
A clinician can try to balance the system by adjusting the intensity of stimulation, but there are limits to how precisely it can be calibrated.
Krehbiel was aware of these shortcomings, and it contributed to his sense that DBS was a treatment of last resort. In the late 2010s, his neurologist hinted that big improvements were on the way. 'So I thought, wait for the new technology.'
Catching waves
Brain-wave activity is different in people with and without Parkinson's disease. In people with Parkinson's, there are noticeable differences at one range of frequencies, known as β-oscillations (between about 13 and 30 hertz), in a region deep in the brain called the basal ganglia. This region processes sensorimotor, cognitive and mood information.
β-oscillations have become an important marker of motor state. In the early 2000s, researchers at University College London found increasing evidence that people with Parkinson's have intense bursts of activity in this range. When drug treatments are working, these bursts are less exaggerated. The same is true for DBS. The more that stimulation normalizes β-oscillations, the better the relief of some symptoms, says Bronte-Stewart.
Aberrant oscillations were dubbed oscillopathies, and in the 2000s, Medtronic started focusing on developing a device that could both r ead and correct these rhythms, says Tim Denison, a biomedical engineer at the University of Oxford, UK, who was working at the company at the time. 'Just like you can build a radio to tune in to an audio channel, can we build a circuit that will tune in to these oscillopathies and help to guide how to adjust the stimulator?' he asks.
By 2006, Denison and his colleagues had built a 'brain radio', a sensing chip that could tune in to the different frequency bands in which the electrode sits. The next challenge was finding out how changes in particular bands correspond to specific movement problems. That was 'a huge part of the first eight to ten years of the research with the investigational hardware', says Bronte-Stewart. She and other researchers, including Philip Starr at the University of California, San Francisco, used a succession of new prototype devices to map these oscillopathies and adjust to them.
For example, when β-oscillation intensity begins to dip after a dose of medication, aDBS automatically reduces stimulation, keeping β-power in a healthy range. As the medication wears off, it does the opposite (see 'Fine-tuned stimulation'). In 2019, Bronte-Stewart developed one of the algorithms that would underpin aDBS. When she tested it on 13 people with Parkinson's, it improved the halting movements, called bradykinesia, that are associated with the disease. It also helped to reduce the inability to take steps, known as freezing of gait, in a study last year. In a separate study, Starr found that aDBS shortened the duration of volunteers' most bothersome motor disturbances, but without aggravating side effects.
Other studies have suggested that aDBS reduces speech problems, such as slurring, that were another possible side effect of continuous DBS. 'It only suppressed the pathological brain activity,' without suppressing normal speech, says Beudel.
Since 2013, small trials such as these have demonstrated these effects in around 400 people, estimates Robert Raike, the director of neuromodulation research and technology at Medtronic. What was missing was a way to validate these findings in real-world settings: in people's homes and workplaces over a long period of time. Researchers needed a big trial.
A personalized device
Any Medtronic DBS implant manufactured after 2020 has the ability to be switched into adaptive stimulation mode. If people were enrolled in a clinical trial after 2020, their implant's experimental capabilities could be activated by a firmware update, 'a software unlock, like your iPhone', says Raike. This approach opened up a large pool of possible trial participants. And the capability could be turned back off at the end of the trial.
After two months with continuous DBS, Bronte-Stewart unlocked Krehbiel's device. It continued to keep his tremor at bay. He needed fewer drugs.
Other trial volunteers have reported similar improvements, along with a reduction of symptoms associated with continuous stimulation. Although she is not permitted to discuss the results, which are still pending publication, Bronte-Stewart points to data presented at a 2024 conference. Of 45 volunteers in the trial who were given the choice to revert to the continuous DBS or to retain the new adaptive functionality for a further long-term follow-up, 44 chose to stay on aDBS, Krehbiel among them. 'I would not have considered for more than 30 seconds reverting back,' he says. 'I was feeling good and didn't much care why.'
Beudel saw a broadly similar trend among his participants. 'It's no secret that the results were positive,' he says. 'We now see patients from all over the country coming to our centre saying that they want the aDBS.'
Since the new system was approved earlier this year, the upgrade has been available to anyone with one of the post-2020 devices. Beyond straightforward symptom relief, these users might see beneficial effects that go beyond controlling motor symptoms.
For example, Parkinson's disease notoriously interferes with sleep, and as the medicine wears off at night, problems emerge that range from insomnia to hallucinations. Sleep deprivation, in turn, worsens the symptoms. 'It is a vicious circle,' says Beudel.
Adaptive DBS could reduce sleep disturbances by automatically adjusting to the sleep-induced changes in β-oscillations.
And better sleep might, in turn, protect the brain. If it does, says Denison, aDBS could shed light on the tantalizing but controversial hypothesis that DBS protects the brain when implanted earlier in Parkinson's disease progression.
Beyond Parkinson's
It's not just people with Parkinson's who might benefit from the new therapy. Slightly more than one-quarter of the estimated 230,000 people with a DBS implant use it to manage other diseases, including dystonia — a movement disorder that causes muscles to contract — essential tremor and OCD.
Researchers are working to identify the associated oscillopathies to allow them to extend aDBS to these populations, and to those whose conditions have not yet been approved for any form of DBS, including Tourette's syndrome. Beudel is exploring oscillopathies that precede the onset of tremor. Michael Okun, a neuroscientist at the University of Florida in Gainesville, has identified oscillations that could be quashed to dial down tics in Tourette's syndrome.
And although the evidence for psychiatric conditions is not yet as strong, says Starr, 'they might have oscillopathies that could be DBS targets.' OCD is especially promising, says Damiaan Denys, a psychiatrist at the University of Amsterdam. In a soon-to-be-published study, he and his team found clear associations between compulsions and specific brain signatures. 'We are near to finding some of these neurological imprints,' he says.
Adaptive DBS has also raised hopes for treatment-resistant depression, which would represent a much larger market than Parkinson's disease. Although DBS is not approved for this condition anywhere in the world, a few hundred people have had experimental implants.
Helen Mayberg, a neurologist at Icahn School of Medicine at Mount Sinai in New York City, ran two of the largest trials for depression so far. Both failed to meet their primary endpoint. Mayberg got one of Medtronic's early prototype brain radios to examine the potential role of oscillations in depression. The condition is complicated. Like Parkinson's, it has many symptoms, but unlike Parkinson's, no specific abnormal oscillations have been associated with it. 'If you round up ten people with depression,' says Alik Widge, a psychiatrist and biomedical engineer at the University of Minnesota, 'you would not see the same oscillopathy.'
But Mayberg might be zeroing in on a signal that is associated with individuals getting better: this brain-oscillation pattern emerges as symptoms recede. A month after the brain signal disappeared in one participant with depression, they relapsed.
This work is in its early days, but Mayberg thinks the sensing capabilities of modern devices might one day provide a 'check engine' warning light for possible relapse.
Overcomplicating the problem?
As Medtronic and other companies continue to enhance their DBS systems, the number of electrodes and their sophistication has risen swiftly. Some researchers, including Denison and Bronte-Stewart, say that the line is blurring between DBS and brain–computer interfaces.
The enhanced sophistication puts pressure on the clinicians in charge of managing the complex device settings. 'Who is going to program these?' asks Okun. He worries that the proliferation of smarter devices could make them, paradoxically, less accessible to people owing to the already-huge demands on clinicians' time.
Medtronic is working on more-automatic programming to save time: one new technology, approved this year, streamlines the process by which the clinician programs the device. Artificial intelligence might refine settings further; the US Food and Drug Administration is developing new standards for automation. Any further advances, however, will require more large studies, such as ADAPT-PD and the smaller studies that led up to it. These are not cheap. 'Every patient can cost a million bucks or more,' says Okun. But the future of a major funding source for DBS is in doubt. Even before the new US administration began slashing funds for medical research, last year Congress made a 40% cut to the BRAIN Initiative, the US National Institutes of Health's neurotechnology innovation accelerator that has provided instrumental support for DBS research. 'I think we're all worried about where the funding will come from to develop these types of studies,' says Bronte-Stewart, although even now, other countries are taking up the slack.
All the while, the number of people with Parkinson's is expected to nearly double globally by 2050: to 25 million.
To meet that need, the goal is to make the process as accessible as it was for Krehbiel. 'I had the opportunity to get the secret sauce,' he says, 'so why not go for it?'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Hill
23 minutes ago
- The Hill
Scientists warn of toxic ‘forever chemicals' in reusable period products
Many reusable menstrual products that have gained increasing popularity among teens are packed with toxic 'forever chemicals,' a new study has found. Among the biggest repeat offenders are washable pads and underwear, according to the study, published on Tuesday in Environmental Science & Technology Letters. And as more consumers opt for multi-use products over their disposable counterparts, the study authors expressed cause for concern. 'Since reusable products are on the rise due to their increased sustainability compared to single-use products, it's important to ensure that these products are safe,' co-author Marta Venier, an associated professor at the University of Notre Dame, said in a statement. 'This is crucial, especially for adolescents and young women, who are more vulnerable to potential negative health effects,' Venier added. The compounds in question are known as per- and polyfluoroalkyl substances (PFAS) and are prevalent in numerous household items, such as waterproof apparel, nonstick pans and various personal care products. There are an estimated 15,000 types of PFAS, all of which are manmade, and some of which have been linked to cancers and other severe illnesses. These so-called 'forever chemicals' linger nearly interminably in the environment and up to several years in the human body. Previous research in China sounded the alarm on the prevalence of PFAS in that country's personal hygiene products, including in sanitary pads, panty liners, tampons, paper diapers, menstrual cups and bactericidal liquids. In addition, a 2020 Sierra Magazine article — which included the participation of Graham Peaslee, senior author of the current study — identified 'intentional fluorine use' in one type of period underwear, which led to a lawsuit and $5 million settlement with the brand. To identify PFAS presence in products, scientists typically begin by deploying a broad-stroke screening tool: the assessment of total fluorine in a sample. They generally deem fluorine usage as 'intentional' — or deliberate in a product's formulation, as opposed to accidental contamination — when levels surpass a specific safety threshold. In the current study, the researchers narrowed their focus on 59 reusable hygiene products — such as period underwear, reusable pads, menstrual cups and reusable incontinence underwear and pads — from North America, South America, Europe, Asia and the Pacific. The products, they explained, first underwent total fluorine screenings using a technology called particle-induced gamma-ray emission spectroscopy. These preliminary screenings showed that period underwear and reusable pads likely had the highest rates of intentional PFAS use: 33 percent and 25 percent of items in each of these product categories, respectively. The findings applied to markets across the globe, with intentional fluorination spotted in seven pairs of South American underwear, four North American pairs and two European pairs, according to the study. Following the initial fluorine scans, the scientists then chose 19 products for targeted analyses of 31 'ionic' and 11 'neutral' types of PFAS. Ionic PFAS are those molecules that can 'dissociate' in the environment, becoming highly mobile and capable of widespread contamination. Among the most notorious types of ionic PFAS are legacy compounds like PFOA and PFOS, which have largely been phased out of production but remain in the environment due to their persistence. Neutral PFAS, on the other hand, do not dissociate and were previously thought to be less toxic. But scientists have been challenging that assumption, as these compounds are highly volatile and can serve as precursors for ionic PFAS. In the more precise PFAS tests for the 19 period products, the researchers detected the compounds in 100 percent of the products, with two types of neutral PFAS — 6:2 and 8:2 fluorotelomer alcohols (FTOH) — boasting the most abundant presence. Co-author Sydney Brady, a PhD candidate in Venier's group, stressed in a statement that 8:2 FTOH was one of the most common types of PFAS in the North American items, despite its elimination from food packing by manufacturers. That phase-out, Brady explained, occurred due to Food and Drug Administration concerns about the chemical's 'persistence in the body after dietary exposure.' 'Notably, 8:2 FTOH can be transformed into more toxic PFOA once inside the body,' Brady warned. While recognizing that far less research exists on PFAS exposure via skin versus food or water, the authors cited initial studies on dermal absorption as a potentially 'significant exposure pathway for PFAS when present in feminine hygiene products.' 'Feminine hygiene products stay in contact with the skin for extended periods of time,' Venier said. 'The risks from the dermal absorption of PFAS, especially neutral PFAS, are not well understood.' As such, the researchers called for further studies to define the risk of PFAS exposure via human skin. In addition, after identifying at least one sample per product category that contained zero intentionally added PFAS, they stressed that safer and healthier alternatives can likely be manufactured without them.


Bloomberg
an hour ago
- Bloomberg
RFK Jr. Turns to Fringe Medical Journal to Find New Hires
George Tidmarsh is a millionaire co-founder of a biotech firm, serial entrepreneur, neonatologist and adjunct professor at Stanford University. But his part in creating a fringe medical journal is the role that stands out as he takes a top post at the US Food and Drug Administration. Tidmarsh, who will lead the Center for Drug Evaluation and Research, is at least the fifth person appointed to a federal health agency under the helm of Robert F. Kennedy Jr. this year connected to the Journal of the Academy of Public Health.


National Geographic
an hour ago
- National Geographic
What causes Parkinson's disease? Scientists uncover an unexpected new clue.
A computer illustration of human pegivirus, an RNA (ribonucleic acid) virus scientists believe may be linked to Parkinson's disease. Illustration by Kateryna Kon, Science Photo Library A recent study linking human pegivirus to Parkinson's is leading scientists to examine the connection between other viral infections and neurodegenerative diseases. More than 10 million people worldwide are living with Parkinson's disease, a progressive neurodegenerative disorder that leads to symptoms such as tremors, slow movement, limb stiffness, and balance issues. Scientists still don't know what causes the disease, but it's thought to develop due to a complex mixture of genetic and environmental factors, and treatment is still quite limited. But new research is putting scientists one step closer to some possible answers. In a recent study published in JCI Insight, researchers found a common virus, called human pegivirus (HPgV), in the brains of patients who had Parkinson's disease when they died. Although HPgV infections don't usually cause symptoms, researchers believe the virus may be playing a role in the development of Parkinson's. 'The hypothesis is that a long-term, low-burning infection might lead to these sorts of diseases,' such as Parkinson's disease and other neurodegenerative disorders, says Barbara Hanson, a researcher at Northwestern University Feinberg School of Medicine, and one of the authors of the paper. Here's what we know so far. Colored Magnetic Resonance Imaging (MRI) scan showing the brain of a 65-year-old patient with Parkinson's. New research suggests that viral infections can be at play in the development of the disease. Photograph by Zephyr/Science Photo Library Over 500 viruses screened In this study, researchers screened for over 500 viruses in the autopsied brains of 10 patients who had Parkinson's disease and compared them to the autopsied brains of 14 control patients, who were matched for age and gender. In five of the patients with Parkinson's, they found the presence of HPgV, while none of the control patients had the virus. In order to bolster their findings, researchers conducted follow-up experiments that looked at the blood samples of patients who were in different stages of Parkinson's disease. What they found was that patients who had Parkinson's and were positive for HPgV had similar immune system responses, including a lower level of an inflammatory protein called IL-4, which can either promote or suppress inflammation depending on the situation. They also found that patients who had a specific Parkinson's-related gene mutation had a different immune system response to HPgV, compared to patients with Parkinson's who didn't have the mutation. 'It was a very thorough study,' says Margaret Ferris, a neurologist and researcher at Stanford University who was not part of the study. She adds that this offers a possible mechanism for the interaction between genetics and environment. Although the presence of HPgV in the brains of people with Parkinson's disease is suggestive of a link, the full answer of what causes the neurodegenerative disease is more complex. Parkinson's disease has always been hard to study, due to the fact that it develops slowly, over many years, and is difficult to diagnose in the earlier stages. 'One of the hard things about investigating neurodegenerative disorders is that it is very hard to identify people who will get neurodegenerative disorders, but don't yet have them, and to study and watch them,' Ferris says. Further complicating this matter is the fact that there doesn't seem to be one single trigger for Parkinson's disease. 'It is difficult to determine the causes of Parkinson's, because they are likely multifactorial,' says William Ondo, a neurologist at Houston Methodist Hospital, who specializes in treating patients with movement disorders such as Parkinson's disease. Ondo was not part of the study. Currently, Parkinson's disease is believed to develop from a complex mixture of genetic and environmental factors, with individual triggers varying from one person to another. This makes studying the potential causes of the disease quite challenging, and means that there still aren't definitive answers to what can trigger the condition. It's likely that some people may develop Parkinson's disease as a result of multiple triggers. 'Everyone is on their own path,' to developing Parkinson's disease, says Erin Furr-Stimming, a neurologist at McGovern Medical School at UTHealth Houston, who was not part of the study. In recent years, there has been a growing body of evidence to suggest a link between viral infections and the development of neurological diseases, such as multiple sclerosis, Alzheimer's, and Parkinson's. This includes the recent discovery that Epstein-Barr virus is a major trigger for multiple sclerosis, as well as a number of associations between viral infections and neurodegenerative conditions. Parkinson-like symptoms have also been triggered by a number of viral infections, such as West Nile virus, St. Louis Encephalitis virus, and Japanese Encephalitis B Virus. As Hanson notes, inflammation in the brain has been linked to the development of neurodegenerative disorders, with viral infections being a potential trigger for this inflammation. 'Any amount of inflammation in the brain can trigger a number of cascades that lead to the loss of normal homeostatic brain function,' Hanson says. 'It's possible that viral infections are one of those triggers that lead to inflammation in the brain.' Other potential reasons that viral infections may lead to neurodegeneration include direct damage to neurons from the virus, or the accumulation of misfolded proteins. However, while this recent study offers evidence of a suggested link between HPgV and the development of Parkinson's disease, there's still more research needed before a clear link between the two can be established. 'This study doesn't show a cause-and-effect relationship—it just suggests there may be a relationship between pegivirus and Parkinson's,' says Joseph Jankovic, a neurologist and director of the Parkinson's Disease Center and Movement Disorders Clinic at Baylor College of Medicine. In order to understand the connection further, Jankovic says, 'this study needs to be replicated in a different cohort of patients.'